NCT06422117View on ClinicalTrials.gov

Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

408

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

July 30, 2027

Study Completion Date

August 7, 2027

Conditions
Central Neuropathic Pain
Interventions
DRUG

HSK16149 20mg-40mg BID

Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;

DRUG

Placebo

Placebo, oral, 2 capsules twice daily

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY